Register entryRepackager / relabeller
- Registered sites
- 1
- Active NDC listings
- 5
- Live patents
- 27
- Exclusivities
- 1
- Shortage listings
- 2
- Countries
- 1
- Base
- Austria
Authorisation
Registered operations
Labelling1Packaging1Relabelling1Repackaging1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| pharmaand GmbH Zweigniederlassung ScheibbsRegistrant: pharmaand GmbH | Rutesheimer Stra�e 17, Scheibbs, 3270, Austria (AUT) | Labelling, Packaging, Relabelling, Repackaging | 3039485501301124211 |
Alert
Drug shortage listings
2| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Peginterferon alfa-2a InjectionAntiviral | Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4) | Resolved | - | 24 Jan 202527 Aug 2026 |
| Peginterferon alfa-2a InjectionAntiviral | Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1) | Resolved | - | 24 Jan 202527 Aug 2026 |
Catalogue
Drug listings by form and route
55 active NDC listings: 5 human prescription drug. By marketing category: NDA 3, BLA 2.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 3 |
| injection, solution | 2 |
| Route | NDCs |
|---|---|
| oral | 3 |
| subcutaneous | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| pharmaand gmbh | 5 |
Exclusivity
Patents and exclusivities
27| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8071579 | RUBRACArucaparib camsylate | use | Aug 2027 |
| 8143241 | RUBRACArucaparib camsylate | use | Aug 2027 |
| 10278974 | RUBRACArucaparib camsylate | product | Feb 2031 |
| 8754072 | RUBRACArucaparib camsylate | substance, product | Feb 2031 |
| 9045487 | RUBRACArucaparib camsylate | substance, product | Feb 2031 |
| 9861638 | RUBRACArucaparib camsylate | use | Feb 2031 |
| 8859562 | RUBRACArucaparib camsylate | use | Aug 2031 |
| 10130636 | RUBRACArucaparib camsylate | use | Aug 2035 |
| 9987285 | RUBRACArucaparib camsylate | product | Aug 2035 |
| Product | Exclusivity | Until |
|---|---|---|
| RUBRACARUCAPARIB CAMSYLATE | I-982 New indication | Dec 2028 |
Catalogue
Marketed products
5| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Pegasys | peginterferon alfa-2a | injection, solution, subcutaneous | 82154-0449BLA |
| Pegasys | peginterferon alfa-2a | injection, solution, subcutaneous | 82154-0451BLA |
| Rubraca | rucaparib | tablet, film coated, oral | 82154-0783NDA |
| Rubraca | rucaparib | tablet, film coated, oral | 82154-0784NDA |
| Rubraca | rucaparib | tablet, film coated, oral | 82154-0785NDA |
Enquiry
Common questions
- Is pharmaand GmbH FDA approved?
- pharmaand GmbH holds 1 FDA-registered establishment in Austria. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are pharmaand GmbH's registered sites?
- The FDA register lists Scheibbs. Registered operations: labelling, packaging, relabelling, repackaging.
- What drugs does pharmaand GmbH make?
- 5 products are listed under pharmaand GmbH in the openFDA NDC Directory, most often as tablet, film coated; injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.